Antonio González-Martı́n
Gynecologic Oncology Group · 686 works · 36,195 citations · h-index 67
Top works
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
- Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
- Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
- Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial
- ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
- Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
- Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
- Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial
- Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study
- Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial
- Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- EP233/#541 Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease following first-line chemotherapy: PRIMA/ENGOT-ov26/GOG-3012 post-hoc subgroup analysis
- COVID-19 Global Pandemic: Options for Management of Gynecologic Cancers
- Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up